Scientists have identified a new gateway into human cells that could make gene therapies safer and more effective. The discovery of AAVR2 receptor allows for lower doses of virus to be used in treatment, reducing side effects and costs while improving patient outcomes.
Researchers have developed a new nasal vaccine that induces potent lung immunity and protects against SARS-CoV-2 infection in mice. The vaccine approach, which targets the nose, airways, and lungs, has shown promising results in preventing COVID-19 infection.
Researchers have developed genetic testing to diagnose cardiomyopathy in children, identifying those at risk of heart failure and requiring a transplant. The test provides precise clinical diagnosis, enabling targeted treatment options and reducing the need for life-threatening interventions.
A world-first study reveals why people with COPD are at higher risk of developing severe COVID-19. Researchers found that COPD airway cells had a 24-fold greater infection with SARS-CoV-2, leading to increased viral load and inflammatory responses.
Researchers found significant differences in gut microbiome and metabolite profiles between COPD patients and healthy individuals. The study suggests that stool sampling could be used to non-invasively diagnose and monitor for COPD.
Centenary Institute scientists discovered that two key proteins involved in blood clotting and immunity exist in multiple disulphide-bonded states. This finding has significant implications for drug development and the fight against disease, as different states of a protein may bind more or less preferentially to drugs.
Researchers have developed a new type of vaccine targeting tuberculosis, providing substantial protection against the deadly disease. The early-stage vaccine was shown to be effective in pre-clinical laboratory settings and demonstrated its ability to stimulate the immune response in the lungs.
A recent study found that the use of advanced imaging equipment like cardiac MRI is driving a significant increase in the diagnosis of Left Ventricular Non-Compaction (LVNC) in adults, raising questions about its clinical utility and potential for over-diagnosis.
Researchers at the Centenary Institute discovered that the tuberculosis bacterium hijacks platelets from the body's blood clotting system to weaken immune systems. Using anti-platelet drugs like aspirin, they were able to prevent hijacking and allow the body to control infection better.
Researchers have identified a drug that inhibits the signalling pathway of enzyme MEKK3, a process contributing to cerebral cavernous malformations (CCM), a leading cause of stroke in young people. A suitable candidate, Ponatinib, is currently used to treat cancer patients and may offer a non-invasive treatment option.
Researchers at Centenary Institute used a super-resolution microscope to study the role of DPP9 in cell movement. They found that inhibiting this enzyme can slow down living cancer cells and prevent tumors from growing or spreading.
Researchers have identified how golden staph bacteria target and destroy key immune cells, disrupting the body's defense against infection. By visualizing this process using advanced microscopy techniques, the team gained insights into how golden staph evades the immune system and causes tissue damage.
A study published in Cell has confirmed that non-coding DNA, previously considered 'junk', plays a crucial role in regulating cell development. The researchers found that certain white blood cells use introns to control the activity of genes involved in their function.
Researchers have identified a new type of immune cell in the skin that plays a role in fighting parasitic invaders and could be linked to eczema. The discovery sheds light on the causes of allergic skin diseases and offers new hope for treating hundreds of millions of people worldwide.
A genetic study in Vietnam aims to find out why only one in ten people carrying the tuberculosis bacterium become sick. The research, led by Australian scientist Dr Greg Fox, seeks to identify genes that increase TB risk.
Researchers at Centenary Institute found prostate cancer cells have more pumps than normal, allowing them to take in leucine and outgrow normal cells. Disrupting these pumps slowed cancer growth by as much as 50%, offering hope for a treatment that slows tumor growth without surgical removal.
Centenary Institute researchers have identified a set of immune cells in the outer layer of the skin that prevent the immune system from attacking friendly bacteria. This discovery opens up new possibilities for treating inflammatory bowel disease and other immune-mediated disorders.
Scientists at Centenary Institute discovered that liver cells can engulf and destroy T-cells, reducing organ rejection in transplants and potentially fighting hepatitis and other chronic liver diseases. The discovery opens up new approaches to transplant rejection and treatment of liver diseases, which affect millions worldwide.
The new BD LSR-9 Flow Cytometer with its nine lasers will help Australian researchers analyze rare cell populations more accurately and directly. This technology will aid in fighting against various life-threatening diseases, including cancer and asthma.
Researchers at the Centenary Institute discovered a new death pathway that can break drug resistance in ovarian cancer. The treatment, FTY720, kills ovarian cancer cells through necrosis, making it resistant to relapse. Further clinical trials are needed to confirm its effectiveness.
A team of researchers has found a way to increase the number of blood-forming stem cells by using a unique stretchy surface. This breakthrough could revolutionize stem cell transplants by generating up to three times more stem cells than current methods.